Samuel Agresta M.D., M.P.H.

Dr. Agresta has an established track record of global clinical drug development in solid tumors and hematologic malignancies, including recent approval of multiple cancer medicines. Dr. Agresta is currently Chief Medical Officer of Foghorn Therapeutics. Prior to Foghorn, Dr. Agresta served as Chief Medical Officer of Infinity where he led the company’s clinical strategy including the design of MARIO-3 and MARIO-275, Infinity’s Phase 2 clinical studies IPI-549. Prior to Infinity, Dr. Agresta was vice president and head of clinical development at Agios Pharmaceuticals, Inc. During Dr. Agresta’s six plus years at Agios, he was responsible for the successful development of novel targeted oncology medicines, including IDHiFA® for patients with IDH2 mutation positive AML and TIBSOVO® for patients with IDH1 mutation positive AML, as well as the development of the targeted agent, AG-348, currently in Phase 3 development for patients with pyruvate kinase deficiency, a rare genetic disease. Prior to Agios, Dr. Agresta held positions of responsibility in oncology clinical development, Phases I-III, at Merrimack Pharmaceutical and Genentech, Inc., including the development of Onivyde®, for patients with pancreatic cancer and Kadcyla®, a novel targeted oncology medicine for patients with HER2 positive breast cancer. Prior to his industry experience, Dr. Agresta was on the oncology faculty at the Moffitt Cancer Center where he specialized in adolescent sarcoma care and participated in numerous industry trials.

Dr. Agresta received his medical degree, internal medicine training, and served as chief resident at Tulane University School of Medicine in New Orleans. While in medical school, he also received a Master’s Degree in Public Health and Tropical Medicine from Tulane University School of Public Health. He completed his medical oncology fellowship at the University of South Florida and Moffitt Cancer Center Cancer where he also received a Master’s Degree in Clinical Investigation from the University of South Florida.